Emerging within the UK, retatrutide, a novel compound , is generating considerable excitement within the scientific community regarding its potential for body control . This dual GIP and GLP-1 receptor agonist seems to offer a significant benefit over existing therapies, showing promising results in initial clinical studies . Researchers suggest it